Search Results
Jan 10, 2026, 10:00 ET RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer
each); cerebral infarction, pulmonary embolism (PE), and COVID-19 infection (0.5% each); and ILD/pneumonitis, acute respiratory distress syndrome (ARDS), and cardiopulmonary arrest (0.2% each).RYBREVANT® with Carboplatin and PemetrexedIn MARIPOSA-2 (n=130), the
More news about: Johnson & Johnson
Dec 22, 2025, 08:46 ET Aqualung Therapeutics Receives FDA Clearance for Phase 2a Lung Fibrosis Study
the company's second FDA-approved Investigational New Drug application (IND) following its 2022 clearance for acute respiratory distress syndrome (ARDS). Upon the next round of funding, the company will initiate the multicenter PAISANO trial – Preventing the Advance of Lung
More news about: Aqualung Therapeutics
Dec 17, 2025, 18:49 ET U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)
each); cerebral infarction, pulmonary embolism (PE), and COVID-19 infection (0.5% each); and ILD/pneumonitis, acute respiratory distress syndrome (ARDS), and cardiopulmonary arrest (0.2% each).RYBREVANT® with Carboplatin and PemetrexedIn MARIPOSA-2 (n=130), the
More news about: Johnson & Johnson
Dec 14, 2025, 19:22 ET Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial
other diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.Cynata Therapeutics encourages all current investors to go paperless by registering their details with the
More news about: Cynata Therapeutics
Nov 19, 2025, 10:00 ET FYR Bio and NuvOx Therapeutics Awarded NCI Direct-to-Phase II SBIR Grant to Advance Liquid-Biopsy Collaboration in Phase IIb Glioblastoma Trial
oxygen, is responsible for resistance to cancer treatment, brain damage in stroke, and the death of patients with acute respiratory distress syndrome (ARDS). The company's drug candidate - NanO₂ represents a potentially disruptive platform technology addressing multiple unmet needs,
More news about: FYR Bio
Nov 18, 2025, 12:10 ET Dynarex Expands Resp-O₂™ Line with Vortex 72 Closed Suction Catheters
Continuous Airway Management: Allows suctioning without interrupting ventilation, supporting stable oxygen delivery for patients with ARDS, COPD, and neuromuscular conditions. Reduced Clinical Burden: Fewer catheter
More news about: Dynarex Corporation
Nov 12, 2025, 16:05 ET Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update
proprietary nafamostat formulation for direct IV infusion that may be investigated and developed for the treatment of acute respiratory distress syndrome (ARDS), disseminated intravascular coagulation (DIC), acute pancreatitis or as an anti-viral treatment, amongst other potential targets.
More news about: Talphera, Inc.
Nov 01, 2025, 13:59 ET Ajay Devgn et Cartel Bros' The GlenJourneys remporte un grand succès sur la scène internationale avec le titre de "Meilleur whisky écossais single malt" à l'IWS 2025 et une médaille d'or aux Spirits Selection Awards au Mexique.
a-scene-internationale-avec-le-titre-de-meilleur-whisky-ecossais-single-malt-a-liws-2025-et-une-medaille-dor-aux-spirits-selection-awards-au-mexique-302601661.html
More news about: GLENJOURNEYS
Oct 28, 2025, 07:00 ET In Memoriam: Dr. Robert Hawes Bartlett (1939-2025) - Father of Extracorporeal Membrane Oxygenation (ECMO) and Former CytoSorbents Chief Medical Officer
contribution was his early recognition of how CytoSorb could be combined with ECMO to treat severe acute respiratory distress syndrome (ARDS) and achieve 'Enhanced Lung Rest'. ARDS afflicts hundreds of thousands to over a million patients worldwide each year, and during the COVID-19 pandemic, contributed to
More news about: Cytosorbents Corp
Oct 21, 2025, 08:30 ET Talphera Announces the Appointment of Joe Todisco to Board of Directors
proprietary nafamostat formulation for direct IV infusion that may be investigated and developed for the treatment of acute respiratory distress syndrome (ARDS), disseminated intravascular coagulation (DIC), acute pancreatitis or as an anti-viral treatment, amongst other potential targets.
More news about: Talphera, Inc.
Oct 19, 2025, 10:30 ET Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer
each); cerebral infarction, pulmonary embolism (PE), and COVID-19 infection (0.5% each); and ILD/pneumonitis, acute respiratory distress syndrome (ARDS), and cardiopulmonary arrest (0.2% each). RYBREVANT ®
More news about: Johnson & Johnson
Oct 09, 2025, 10:30 ET ECMO Machine Market worth US$0.86 billion by 2030 with 5.8% CAGR | MarketsandMarkets™
culminating in a forecasted valuation of US$0.86 billion by the end of the period. Cardiopulmonary conditions such as acute respiratory distress syndrome (ARDS), COPD, and advanced heart failure are becoming increasingly prevalent worldwide due to pollution, lifestyle changes, and aging populations. ECMO machines
More news about: MarketsandMarkets
Sep 30, 2025, 07:30 ET Inflammatix Announces Three Landmark Publications in Nature Medicine that Redefine Acute Infection and Sepsis Diagnosis and Treatment
Dysregulation Evaluation Framework) — to identify shared biological pathways across critical illnesses including sepsis, acute respiratory distress syndrome (ARDS), trauma, and burns. Developed by the SUBSPACE consortium, which analyzed transcriptomic data from more than 7,000 patient samples across 37 cohorts
More news about: Inflammatix
Sep 29, 2025, 07:00 ET CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen
ARDS,
More news about: Cytosorbents Corp
Sep 18, 2025, 06:00 ET Ventilators Market Poised to Surpass USD 7.42 Billion by 2030, Says Mordor Intelligence
as healthcare systems adapt to higher incidences of chronic obstructive pulmonary disease (COPD), asthma, and acute respiratory distress syndrome (ARDS). Technological innovations such as portable designs, improved patient-ventilator synchronization, and AI-enabled monitoring are reshaping clinical efficiency
More news about: Mordor Intelligence Private Limited
Sep 17, 2025, 08:30 ET Advancing Cancer Research Brings New Hope for Patients Worldwide
OT-101 is not confined to oncology. During the COVID-19 crisis, the drug was explored for its ability to treat acute respiratory distress syndrome (ARDS) linked to severe viral infection. Initial results indicated potential benefits in controlling immune system overreaction and lowering mortality in
More news about: NetworkNewsWire
Sep 15, 2025, 08:30 ET Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth
promise of OT-101 extends beyond oncology. During the COVID-19 pandemic, the candidate was tested for use in acute respiratory distress syndrome (ARDS) associated with severe viral infection. Early findings showed potential in mitigating immune overactivation and reducing mortality in critically
More news about: NetworkNewsWire